GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Ligand Pharmaceuticals Incorporated (LGND) [hlAlert]

Rating:
Buy LGND
up 53.27 %

Ligand Pharmaceuticals Incorporated (LGND) rated Buy with price target $96 by MLV & Co

Posted on: Thursday,  Feb 13, 2014  8:25 AM ET by MLV & Co

MLV & Co rated Buy Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) on 02/13/2014. Previously MLV & Co rated Buy Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
on 02/10/2014., when the stock price was $61.49. Since then, Ligand Pharmaceuticals Incorporated has gained 53.28% as of 09/30/2015's recent price of $94.25.
If you would have followed the previous MLV & Co's recommendation on LGND, you would have gained 53.27% of your investment in 597 days.

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

MLV & Co is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/13/2014 8:25 AM Buy
None
79.15 96.00
as of 10/17/2014
1 Week up  12.66 %
1 Month down  -2.07 %
3 Months down  -1.16 %
1 YTD down  -36.74 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/10/2014 8:25 AM Buy
None
61.49 82.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy